Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug exposure are critical.
Continuous-Transit Delivery Systems
These systems are designed to pass through the gastrointestinal (GI) tract while gradually releasing the drug. They include a range of mechanisms, such as hydrophilic or hydrophobic matrices, multilayer tablets, and reservoir-based designs. Hydrophilic matrix systems, like those used in Glucophage XR for metformin, swell upon contact with gastrointestinal fluids, forming a gel barrier that modulates drug diffusion. Osmotic pump systems, such as Procardia XL, use osmotic pressure to drive a controlled release of drugs like nifedipine through a semipermeable membrane over 24 hours. Ion-exchange resins and multilayer tablets also contribute to this category, offering tailored release profiles based on the drug’s physicochemical properties.
Gastroretentive Delivery Systems
Gastroretentive systems aim to extend the residence time of a dosage form in the stomach, which is particularly useful for drugs that are absorbed primarily in the upper GI tract or degrade in the intestine. These systems employ buoyant formulations that float on gastric fluids, mucoadhesive polymers that adhere to the stomach lining, or high-density tablets that resist gastric emptying. An example is the Madopar HBS capsule, which employs a floating mechanism to deliver levodopa and benserazide gradually, optimizing therapeutic outcomes for Parkinson’s disease by maintaining consistent drug concentrations.
Overall, continuous-release formulations represent a critical innovation in pharmacotherapy. They improve drug bioavailability and patient compliance while minimizing side effects associated with peak-trough fluctuations.
Post-oral administration, continuous-release systems deliver drugs at a controlled rate over an extended period.
This maintains steady drug levels, enhancing effectiveness and reducing dosing frequency.
These systems fall into two categories: continuous-transit and gastroretentive systems.
Continuous-transit systems use hydrophilic or hydrophobic matrices, reservoir-type systems, osmotic pumps like OROS, and ion-exchange resins.
The Wellbutrin XL tablet uses a hydrophilic matrix system to release bupropion in a controlled manner. But the Procardia XL tablet uses an osmotic pump with a semipermeable membrane to release nifedipine over twenty-four hours.
Gastroretentive systems prolong stomach retention using mucoadhesive coatings, buoyant formulations, or effervescent agents.
For example, the Madopar HBS capsule employs a buoyant formulation to release levodopa and benserazide in the stomach over an extended period.
These systems benefit chronic conditions like Parkinsonism, diabetes, and hypertension by ensuring consistent drug levels and improving adherence.
繁體中文
